The selective involution of the adrenal zona reticularis (ZR) probably isn't a programmed biological clock, but a "Vascular-Glucocorticoid Trap" (VGT). I'd argue that the centripetal microvascular rarefaction seen in aging [, 2026-03-11] is actively driven by the cortisol produced in the upstream Zona Fasciculata (ZF). This creates a localized "watershed" ischemia. ZR cells, bathed in high concentrations of glucocorticoids that block vascular endothelial growth factor (VEGF), run into a metabolic crisis. They're eventually forced to switch from synthesizing DHEA to p53-mediated apoptosis.

The adrenal blood supply flows from the outer subcapsular plexus inward toward the medulla. This makes the ZR the last to get oxygenated blood and the first to get ZF-derived cortisol. Since glucocorticoids inhibit VEGF and other pro-angiogenic signals, and ZF cortisol production stays stable or even increases as we age [Frontiers in Endocrinology, 2019], the ZR ends up trapped in an "angiostatic bath." It can't trigger the compensatory angiogenesis needed to fix the microvascular rarefaction.

In most tissues, hypoxia stabilizes HIF-1α to help cells survive. But the ZR has a high metabolic demand because DHEA synthesis requires significant mitochondrial flux and P450c17 activity. The combination of hypoxia and high local cortisol likely prevents effective HIF-1α signaling, stabilizing p53 and p21 instead [PMC7774755]. This forces ZR cells into a "metabolic suicide" or senescence, essentially sacrificing themselves to protect the ZF and the cortisol production necessary for immediate survival.

As ZR cells die off [Researcher Life], the systemic Cortisol/DHEA ratio climbs. DHEA usually acts as an antiglucocorticoid, so losing it messes with the negative feedback of the HPA axis [PMC12357812]. This leads to higher evening cortisol, which further suppresses adrenal VEGF expression. It's a self-reinforcing cycle that starves the ZR.

If this is right, the rising Cortisol/DHEA ratio is a biomarker for intra-adrenal vascular collapse. We can test this: localized ZR ischemia should show up on high-resolution contrast-enhanced MRI before clinical adrenopause begins. Also, giving DHEA or localized VEGF-mimetics should theoretically slow down the involution by breaking that angiostatic cycle. The hypothesis is falsifiable, too—if ZR cell loss happens without microvascular rarefaction, or if blocking glucocorticoid receptors in the adrenal doesn't stop ZR atrophy under stress, then the VGT model doesn't hold up.

Ultimately, the ZR isn't just a victim of central brain aging. It's the casualty of a localized, cortisol-heavy environment that becomes unsustainable by our fourth decade [Academic OUP, 2024].